logo
更新:2020-03-06
Safety Physician
面议
上海  | 5年以上  | 硕士,博士  | 社招  | 招1人
已结束
职位详情

Job Responsibility

1.  Responsible for the continued safety assessment, evaluation and risk management of DZ products or product groups in various stages of clinical development

2.  Responsible for continuous efficient evaluation of adverse event and all other safety information in order to predict and manage the safety profile of compounds in clinical development through identifying the need for update to reference safety information and drive proactive implementation of risk management initiatives in accordance with regulatory requirements.

3.  Provides consistent communication of safety topics across all regulatory safety documents,

4.  Proactively evaluates the clinical implications of safety data from clinical studies, literature and other information sources in order to predict / establish the safety profile of compounds in clinical development, including employing expert groups and methodologies, modelling and simulation to manage the risk to patients

5.  Supports key contacts with opinion leaders, as needed

6.  Be responsible for the Clinical Safety monitoring and management plan.Activities include, but are not limited to: definition of identified and potential risks with high level mitigation and minimisation; proposals for mitigation minimisation measures; safety go-no go criteria for the clinical programme; response to regulatory safety queries and definition of the risk component of the benefit/risk assessment.

7.  Reviews and endorses the core Patient Risk Management Plan/Core Patient Risk Log.

8.  Provides expertise to the medical content of the safety specification, pharmacovigilance plan and risk minimisation activities in the core Patient Risk Management Plan, Core Patient Risk Log.

9.  Represents PS on cross-functional Clinical Teams and/or Project Teams for developmental and/or marketed products.

10.  Provides medical input to ensuring that risk-minimisation strategies are implemented appropriately in relevant documents such as product reference safety information.

11. Provides strategic and medical input to project specific safety requirements.

12. Reviews and provides technical input and approval for investigator brochures, protocols, informed consents, final study reports and external data monitoring committees as appropriate.

13. Present safety information at clinical investigator and commercial meetings.

14. Provides medical input to regulatory supporting documentation for labelling updates.

15. Provides medical input into Identification and utilization of appropriate sources of information and database searches to retrieve relevant data for evaluation of signals.

16. Provides medical input to deliver accurate and fit for purpose safety evaluation documents with clear conclusions in response to internal or regulatory authority requests for safety data.


Education, Qualifications, Skills and Experience

1.  Medical degree (eg MD, MBBS)

2.  At least 2 years of clinical experience

3.  At least 5 years of Drug Development/Patient Safety experience (the majority of which should be in industry in Patient Safety) with clear evidence of delivery

4.  Drug Development Experience and Application of Disease and TA knowledge

5.  Excellence in pharmacovigilance Patient Benefit risk assessment

6.  Good spoken English capabilities

工作地址
上海市浦东新区亮景路
点击查看地图
公司介绍
On Nov. 27th, 2017, through a joint venture between AstraZeneca and China Advanced Manufacturing Fund, Dizal Pharma was co-constructed as a world-leading innovative bio-pharmaceutical enterprise. As a new, unique mode of cooperation between SDIC Fund Management Company Ltd. and worldwide privileged research resources in the field of biological pharmacy, Dizal Pharma can not only accelerate the launch and listing of global new drugs in China, bring Chinese patients access to the latest drugs found across the world at once and thus raise the clinical benefits of patients; At the same time, we also take advantages of the global privileged innovative resources, increase China’s core competitive power in the innovation of new drugs, step in the leading branch of international research and development of new drugs and push China into the role of causing both huge and powerful influence in pharmacy industry.
As a new-style joint venture company, besides the project of the transfer of AstraZeneca’s patents, Dizal Pharma also develops the innovation and creation of global First-in-Class drugs.

The R&D (Research and Development) team of Dizal Pharma was AstraZeneca Asia and Emerging Market Research Center. As one of AstraZeneca’s first four R&D centers across the world, it dedicated to analyze the potential scientific mechanism of those most common diseases in Asia and fulfill the particular medical needs of Asian patients. It was one of the few R&D centers established by transnational pharmacy enterprises in China which had the ability to actually research, develop and produce micro-molecular new drugs, the ability to develop produce new drugs independently and completely, and the first-class medical platform in the world.

       迪哲医药,于2017年10月独立运营,是一家研发驱动型生物医药企业,致力于全球创新药物(First-in-class/ Best-in-class)探索、研发以及商业化。

       迪哲医药的前身为阿斯利康亚洲及新兴市场创新研发中心,设立于中国上海,是阿斯利康全球四个研发中心之一(另三个中心分别位于英国剑桥、瑞典哥德堡、美国盖瑟斯堡);是国际一流、高产出的创新药研发机构,拥有全球领先的转化医学和新药分子设计与筛选技术平台;在恶性肿瘤、自身免疫性疾病、肾病等重大疾病的新药研究方面积累了丰富经验。

工商信息
以下信息来自
企业类型
有限责任公司(中外合资)
经营状态
存续
行业类型
研究和试验发展
成立日期
2017年10月27日
注册地址
无锡市新吴区净慧东路汇融商务广场E楼(5号楼)4105室
统一社会信用代码
91320214MA1T6H5736
若用人单位提供虚假招聘信息,以担保或其他任何名义收取财物,扣押或以保管为名索要证件,都属于违法行为,应当提高警惕。
发布于